Let our journalists help you make sense of the noise: Subscribe to the Mother Jones Daily newsletter and get a recap of news that matters.

The ads running in trade journals promised something psychiatrists desperately wanted: a safer antipsychotic. But like so much that comes from the pharmaceutical industry, they present a story of spin.

For years, psychiatrists had been giving mentally ill patients drugs that triggered horrific neurological side effects known as extrapyramidal symptoms (EPS). In the 1990s, pharmaceutical companies led by Janssen Pharmaceutica introduced a new class of “atypical” antipsychotics with eye-catching claims: Not only were they less toxic, their neurological impact was minimal.

“Incidence and severity of extrapyramidal symptoms were similar to placebo,” claimed an ad for Janssen’s Risperdal in the April 1994 American Journal of Psychiatry. A placebo, of course, is a sugar pill with no active ingredients that can cause no side effects. What was missing was context.

The studies these claims were based on were conducted with mentally ill patients who were, to start with, on old generation antipsychotics, usually Haldol. To begin the study, all the patients were abruptly taken off their meds. The placebo group went through Haldol withdrawal, a process known to trigger side effects. The others got Risperdal.

“It’s a huge trick,” claims David Cohen, a professor of social work at Miami’s Florida International University, who has written widely on psychiatric medication. “In the group yanked off Haldol and left with nothing, the extrapyramidal symptoms worsen. Of course they do. They’ve just been yanked off Haldol and their brains are going haywire!”

In fact, many patients on Risperdal in Janssen-sponsored studies did experience EPS—just not at a greater rate than those withdrawn from Haldol.

Doug Arbesfeld, a spokesman for Janssen Pharmaceutica, said there was nothing misleading about the ads for Risperdal. Few schizophrenic patients available for trials are not already on medications, he noted. “Anyone who understands how these studies are constructed would understand that.”

In fact, researchers at McMaster University in Ontario did test patients not previously treated with antipsychotics and found that 59 percent on Risperdal developed Parkinsonism, compared to 52 percent on Haldol.

Risperdal, wrote Richard Horton, editor of the British medical journal, the Lancet, was “a marketing success if nothing else.”


Headshot of Editor in Chief of Mother Jones, Clara Jeffery

It sure feels that way to me, and here at Mother Jones, we’ve been thinking a lot about what journalism needs to do differently, and how we can have the biggest impact.

We kept coming back to one word: corruption. Democracy and the rule of law being undermined by those with wealth and power for their own gain. So we're launching an ambitious Mother Jones Corruption Project to do deep, time-intensive reporting on systemic corruption, and asking the MoJo community to help crowdfund it.

We aim to hire, build a team, and give them the time and space needed to understand how we got here and how we might get out. We want to dig into the forces and decisions that have allowed massive conflicts of interest, influence peddling, and win-at-all-costs politics to flourish.

It's unlike anything we've done, and we have seed funding to get started, but we're looking to raise $500,000 from readers by July when we'll be making key budgeting decisions—and the more resources we have by then, the deeper we can dig. If our plan sounds good to you, please help kickstart it with a tax-deductible donation today.

Thanks for reading—whether or not you can pitch in today, or ever, I'm glad you're with us.

Signed by Clara Jeffery

Clara Jeffery, Editor-in-Chief

payment methods

We Recommend